Despite the above limitations, recent advances in the engineering of skeletal muscle three-dimensional systems using patient-derived induced pluripotent stem cells holds the prospect of providing a physiologically relevant cellular system through which to evaluate and screen potential treatments for skeletal muscle disorders, including RYR1-RM [290–292]. This evidence concerns the gene RYR1 and skeletal muscle disorder.